NCT04161391 2024-06-13Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTurning Point Therapeutics, Inc.Phase 1/2 Terminated41 enrolled 18 charts